Here's how PUBMED.NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

PUBMED . NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Pubmed.ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://pubmed.ncbi.nlm.nih.gov/28178969/.

Title:
Neuroblastoma treatment in the post-genomic era - PubMed
Description:
Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics. The correct stratification of neuroblastoma patients within risk groups (low, intermediate, high and ultra-high) …
Website Age:
27 years and 8 months (reg. 1997-10-02).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is pubmed.ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Pubmed.ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of pubmed.ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Pubmed.ncbi.nlm.nih.gov Make Money? {💸}

We can't see how the site brings in money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Pubmed.ncbi.nlm.nih.gov might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

neuroblastoma, doi, pmid, pubmed, review, pmc, omics, cancer, treatment, alk, drug, therapeutic, neoplasm, clinical, proteins, inhibitors, targets, epub, articles, mesh, feb, patients, trials, crizotinib, lung, free, article, main, ncbi, similar, cited, references, information, resources, molecular, phase, medicine, resistance, therapy, cell, ecollection, shimada, genetics, central, hhs, page, content, homepage, navigation, search,

Topics {✒️}

main page content similar articles cited compounds targeting proteins articles references luksch abstract neuroblastoma targeted therapy small-cell lung cancer antibody-drug conjugate phase i-ii trials resources review topic clinical trials generation alk inhibitors mesh keyword mol cell biochem neuroblastoma patients resistant clin lung cancer therapeutic targets united states government biomed sci early childhood originating o'bryant cl targeting vesicular lgals3bp parp1 gene polymorphisms peripheral neuroblastic tumours clinical phases developed therapeutic strategy therapeutic intervention neural crest cells showing heterogeneous biological downstream signalling pathways health indirect inhibitors alk inhibitors 29466695 alk inhibitors high-throughput technologies alk gene deregulation cited neuroblastoma cells pubmed wordmark pubmed logo omics data neuroblastoma treatment hogarty md neuroblastoma patients neuroblastoma susceptibility neuroblastoma group clinical trials advanced-stage phase ii future oncol

Questions {❓}

  • ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?

External Links {🔗}(61)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • jQuery
  • PhotoSwipe

CDN Services {📦}

  • Ncbi

3.43s.